Nianshuang Wang arrived in the U.S. from China about seven years ago to help explore an obscure niche in structural biology: manipulating coronavirus spike proteins to be more stable and thus better for use in vaccines.
In early 2020 it was Wang who figured out how to make the spike protein on the novel coronavirus bind with human receptors, enabling
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.